lucitanib: Clinical Trials

3 terminated, 2 completed, 2 withdrawn, 1 suspended. 9 Phase 2, 4 Phase 1, 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	9	Terminated 3, Completed 2, Withdrawn 2, Suspended 1, Unknown 1
Phase 1	4	Completed 1, Suspended 1, Terminated 1, Withdrawn 1
Phase 3	1	Unknown 1

Follow lucitanib: new trials by email Literature Review of lucitanib trials Research Report on lucitanib

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy nivolumab, ipilimumab, cabozantinib - Carcinoma, Non-small Cell Lung Cancer	Phase 1 / Phase 2	Withdrawn	Bristol-Myers Squibb		2021-04-15	2023-12-19
This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients AL3810, carboplatin + etoposide, Placebo - Extensive-stage Small Cell Lung Cancer	Phase 2 / Phase 3	Unknown	Haihe Biopharma Co., Ltd.	313	2019-11-14	2020-02-05
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor Lucitanib, Nivolumab - Advanced Solid Tumor, Gynecologic Cancer	Phase 1 / Phase 2	Suspended	Clovis Oncology, Inc.	227	2019-07-29	2022-12-20
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) Rucaparib, Lucitanib, Sacituzumab govitecan - Ovarian Cancer, Triple-negative Breast Cancer	Phase 1 / Phase 2	Terminated	pharmaand GmbH	25	2019-06-28	2024-01-16
Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations Lucitanib - Advanced Cancer	Phase 2	Withdrawn	Teresa Helsten, MD		2017-04-01	2018-08-02
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Lucitanib - Breast Cancer, Metastatic Breast Cancer	Phase 2	Terminated	Clovis Oncology, Inc.	178	2014-09-09	2020-06-23
A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations Lucitanib - Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer	Phase 2	Terminated	Clovis Oncology, Inc.	18	2014-04-01	2019-07-29
A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer lucitanib - Breast Cancer	Phase 2	Completed	Institut de Recherches Internationales Servier	76	2013-12-01	2024-07-25
Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors Lucitanib - Solid Tumors	Phase 1 / Phase 2	Completed	Institut de Recherches Internationales Servier	134	2010-07-01	2024-07-25

Conditions studied

Breast Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Ovarian Neoplasms (2)  ·  Small Cell Lung Carcinoma (2)  ·  Acrocephalosyndactylia (1)  ·  Carcinoma (1)  ·  Carcinoma, Transitional Cell (1)  ·  Endometrial Neoplasms (1)  ·  Fallopian Tube Neoplasms (1)  ·  Genital Neoplasms, Female (1)  ·  Lung Neoplasms (1)  ·  Neoplasms (1)  ·  Triple Negative Breast Neoplasms (1)  ·  Uterine Cervical Neoplasms (1)

Sponsors

Clovis Oncology, Inc. (3)  ·  Institut de Recherches Internationales Servier (2)  ·  Bristol-Myers Squibb (1)  ·  Haihe Biopharma Co., Ltd. (1)  ·  Teresa Helsten, MD (1)  ·  pharmaand GmbH (1)

Countries

United States (6)  ·  Italy (4)  ·  Spain (4)  ·  Belgium (3)  ·  France (3)  ·  Germany (3)  ·  Argentina (1)  ·  Australia (1)  ·  Austria (1)  ·  Canada (1)  ·  China (1)  ·  Denmark (1)  ·  Greece (1)  ·  Hungary (1)  ·  Mexico (1)

Top investigators

Erika Hamilton, MD (1)  ·  Javier Cortes, MD (1)  ·  Nicole Concin, MD (1)  ·  Teresa Helsten, MD (1)

Results publications

PMID 35844029, PMID 25193991

NIH funding

2018 (2)